Linked Life Data

11173725

Source:http://linkedlifedata.com/resource/pubmed/id/11173725

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2001-2-22
pubmed:abstractText
External pump treatment improves glycemic control, particularly thanks to the continuous basal rate. The pharmacokinetics of the short-acting insulin analog lispro allow a better control of post-prandial hyperglycemia than regular insulin. The use of the short-acting insulin analog in the pump improves HbA1c and blood glucose stability, without increasing the risk of hypoglycemia. Frequent blood glucose self-monitoring is required in order to optimize insulin adjustments, using the retro-active method. Systematic monitoring of urine ketones is also required, for an early detection of any interruption in insulin delivery. Under these conditions, this modality of intensified treatment seems very efficient.
pubmed:commentsCorrections
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1262-3636
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
513-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
[How should we use the short-acting insulin analog Lys-Pro in external continuous subcutaneous pumps?].
pubmed:affiliation
Service de Diabétologie, Maladies Métaboliques et Maladies de la Nutrition, Hôpital Jeanne d'Arc, CHU de Nancy, 54201 Toul Cedex, B.P. 303, France.
pubmed:publicationType
Journal Article, English Abstract, Review